PCVX — VAXCYTE INC

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About VAXCYTE INC (PCVX)

VAXCYTE INC (PCVX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Seth Klarman (Baupost Group), valued at $46M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Tracked investors reporting PCVX

  • Seth KlarmanMar 31, 2026
    Baupost Group
    Shares
    800K
    Value
    $46.5M
    % Portfolio
    0.91%
  • Ken GriffinDec 31, 2025
    Citadel Advisors
    Shares
    398.8K
    Value
    $18.4M
    % Portfolio
    0.01%
  • Ray DalioMar 31, 2026
    Bridgewater Associates
    Shares
    12.9K
    Value
    $749.8K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold PCVX?
3 tracked institutional investors disclosed a position in PCVX (VAXCYTE INC) in their most recent 13F filing.
Who is the largest institutional holder of PCVX?
Seth Klarman, Baupost Group, holds the largest disclosed position in PCVX, valued at $46M.
Did institutional ownership of PCVX increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 0 reduced, and 1 fully exited PCVX.
Where does this PCVX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.